Harnessing the Therapeutic Potential of Mitochondrial DNA
CohBar is a clinical-stage biotechnology company exploiting the power of the mitochondria and its encoded peptides to develop potential breakthrough therapeutics targeting chronic and age-related diseases. While extensive work has been conducted on the nuclear genome, we are the first to discover potential therapeutics sourced from the mitochondrial genome.
We developed our Mito+ platform to enable us to identify and develop peptides that we believe have great promise as potential human therapeutics. One of the key early insights that led to the development of CohBar’s novel platform was the recognition that certain mitochondrially encoded peptides produce effects that are not limited to local regulation within the mitochondria and may have important roles to play in critical systemic biological pathways quite distinct from what has traditionally been thought of as mitochondrial function. CohBar is using this novel approach to develop analogs of these natural peptides to treat a variety of serious systemic conditions, with a focus on diseases involving inflammation and fibrosis, including idiopathic pulmonary fibrosis (IPF) and nonalcoholic steatohepatitis (NASH). As analogs of naturally occurring peptides, we expect our product candidates to have better safety and tolerability profiles compared to other drug development approaches focused on non-natural starting points.
As the first company to mine the mitochondrial genome for therapeutically relevant peptides, we have established a robust and growing IP portfolio with 15 issued patents and over 65 patent filings.View Pipeline